View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 17, 2019updated 12 Jul 2022 12:28pm

Grifols reports positive data from Alzheimer’s study AMBAR

Spanish healthcare company Grifols has reported new results from its Alzheimer Management by Albumin Replacement (AMBAR) clinical trial to treat patients with mild and moderate Alzheimer's disease.

Spanish healthcare company Grifols has reported new results from its Alzheimer Management by Albumin Replacement (Ambar ) clinical trial to treat patients with mild and moderate Alzheimer’s disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial investigated the safety and efficacy of short-term plasma exchange and subsequent long-term plasmapheresis using a combination of human albumin infusion and intravenous immunoglobulin.

It aimed to determine if plasma exchange could stabilise disease progression in a total of 496 patients aged 55-85. Changes in cognition and daily activity scores were monitored to measure the treatment’s efficacy.

The latest data from the multi-centre, randomised, blinded, placebo-controlled, parallel-group study revealed a statistically significant 61% decrease in disease progression in moderate Alzheimer’s patients who received the Ambar treatment.

In the same cohort, the therapy demonstrated positive effects on memory, while those with mild disease experienced favourable effects on language and processing speed.

A statistically significant decline of 71% was observed for the Clinical Dementia Rating – Sum of Boxes (CDR-Sb) scale in overall study participants treated with Ambar , compared to placebo.

When the three treatments arms in the trial were assessed separately, the CDR-Sb significance sustained a decline of between 65% and 71% at 14 months.

Further analysis found a decline of 53% in moderate patients, while mild stage subjects showed an improvement. The company noted that this indicates a higher treatment effect for this endpoint in earlier Alzheimer’s stages.

In addition, a statistically significant stabilisation was reported for the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) scale in all treated patients versus placebo.

Grifols Ambar Clinical Program medical director Dr Antonio Páez said: “The new results, together with those presented earlier, show positive effects on the three most important endpoints in Alzheimer’s disease trials: cognition, function, and the combination of both, which is very unique in Alzheimer’s investigation.”

The company presented initial results from the trial at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Spain last October and at the 14th International Congress on Alzheimer’s and Parkinson’s (AD/PD) in March in Portugal.

The new data has been presented at the Alzheimer’s Association International Conference (AAIC) 2019 in the US.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena